CD9 and prostate cancer: To enumerate EVs in human prostate cancer plasma samples isolated by next‐gen ATPS and commercially viable kits, antibodies against EV biomarkers, CD9, CD63 and CD81 were used to label EV subpopulations for nFC analysis (Figure 6D).